Companies / RCE

RECCE PHARMACEUTICALS LTD

ASX:RCEPharmaceuticals, Biotechnology & Life Sciences
305.8M shares on issueASX (delayed) · snapshot 11 Sept 2026326.0M fully diluted+6.6% if every option and right converts$0.37price · delayed$113.1Mmarket cap · indicative

Today’s holders own 93.8% of what they think they own, once every option and right converts.

Low
Dilution risk

Share count grew 29% in 24 months; runway 4–8 quarters; 1 cash raise in 24 months

MinimalVery high
Absolute levels — not a ranking against other companies.
Cash runway4.7 quarters of funding
Share-count growth (24m)29.4%measured to the latest Appendix 2A, not to the share count above
Raise cadence (24m)1 cash raise
Options & rights overhang6.6% of shares
In-the-money supply0.0% of shares
Pending proposed issuesnone

RECCE PHARMACEUTICALS LTD’s ordinary share count stood at 306M as of August 2026. The company completed one capital raise in the past 24 months, a Placement and Share Purchase Plan (SPP) in June 2026, which generated A$6.4M. Options and rights on issue could convert to 20M new shares, representing 6.6% of the current share count, with no options currently in the money; the nearest expiry date is February 2027. As of June 2026, the company reported A$11.1M in available cash, sufficient to cover approximately 4.7 quarters of operations. There are no pending proposed securities issues.

AI-generated summary of this page's cited filings · updated 8 Sept 2026
Get told when this changes
Set up alerts
Daily email alerts cover risk-level moves, new raises, pending proposed issues and option expiries for the companies you follow.
6.6%
Options & rights overhang
0.0%
In-the-money supply
1
Raises · last 12 months
4.7 qtrs
Cash cover · over 4 quarters

Shares on issue — last 2 years

Ordinary shares on issue
Weekly counts from ASX records. Dots mark cash capital raises. Latest count 305.8M per ASX (delayed) (snapshot 11 Sept 2026).
250M275M300MDec 24Oct 25Sept 26Cash raise · 23 June 2026305.8M

Cash runway

4.7 qtrs
More than four quarters of funding at the recent spend rate.
Funds operations to about Aug 2027 at the reported spend rate.
$11.0M cash after burn from the quarter ended 30 June 2026 · Runway is computed from Appendix 4C/5B filings and announced raise proceeds. Filed with the quarterly report: $2.9M cash at quarter end (item 4.6), 10.9 qtrs of funding on the company’s own estimate. Our figure above carries the filed quarter-end balance forward at the reported spend rate and adds announced raise proceeds.
Free account
14 quarters on record — Cash runway history
Quarterly cash, net spend and cover trend from every Appendix 4C/5B on record up to 30 June 2026.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Issuance timeline

Latest 5 filings (Appendix 2A quoted issues, 3G unquoted, 3H cancellations)

DateFormSecurityOn issue, per this filingSource
2 Aug 20262A · quoted issueRCE : ORDINARY FULLY PAID299.7MAppendix 2A
31 July 20262A · quoted issueRCE : ORDINARY FULLY PAID305.5MAppendix 2A
3 July 20262A · quoted issueRCE : ORDINARY FULLY PAID299.5MAppendix 2A
2 July 20263H · cancellationRCE : ORDINARY FULLY PAID299.3MAppendix 3H
1 July 20262A · quoted issueRCE : ORDINARY FULLY PAID299.0MAppendix 2A

Each filing states the count for the security it names, as at its own reference date and in the units of that filing — so the newest row (299.7M) need not equal the current count above (305.8M).

Free account
23 filings on record — Full issuance history
Every quoted and unquoted issue and cancellation on record, plus unquoted securities (Appendix 4.2).
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Capital raises

1 cash raise in the last 24 months · 1 in the last 12 months

$6.4M
Placement and Share Purchase Plan (SPP)
23 June 2026 COMPLETE
Free account
3 raises on record — Full raise history
Issue price, shares issued, brokers and stated purpose for every raise on record.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Forward supply

Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.

Free account
3 dated events on record — Forward supply calendar
Option expiries and proposed issues on one forward timeline, with the securities each could add.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Placement capacity

How much stock a company can place without asking holders. Listing Rule 7.1 allows 15% of ordinary securities in any 12 months, and every Appendix 3B states how much of it an issue uses.

No estimate — the filings already exceed 15% of the share count we can measure, which means securities were added to the base during the year that we cannot see.
Free account
Placement capacity — LR 7.1 / 7.1A
The filings behind the figure: every Appendix 3B in the window with what it says was issued under 7.1 and 7.1A, each row linked to its filing, and how many shares are left.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Pending proposed issues

No proposed issues (Appendix 3B) currently pending.

Options & convertible securities

6.6%
Options & rights overhang · of current shares
0.0%
In-the-money supply · at current price
20.2M
Potential new shares
Feb 2027
Nearest expiry
What a price move would switch on
10.1M20.2M$0.37 now0.25× today ($0.09) — 0 of the priced supply in the money, 0.0% of shares on issue0.5× today ($0.18) — 0 of the priced supply in the money, 0.0% of shares on issue0.75× today ($0.28) — 0 of the priced supply in the money, 0.0% of shares on issue1× today ($0.37) — 0 of the priced supply in the money, 0.0% of shares on issue1.25× today ($0.46) — 0 of the priced supply in the money, 0.0% of shares on issue1.5× today ($0.55) — 0 of the priced supply in the money, 0.0% of shares on issue2× today ($0.74) — 2.5M of the priced supply in the money, 0.8% of shares on issue3× today ($1.11) — 14.0M of the priced supply in the money, 4.6% of shares on issue5× today ($1.85) — 14.4M of the priced supply in the money, 4.7% of shares on issue10× today ($3.70) — 14.4M of the priced supply in the money, 4.7% of shares on issue0.25×0.5×0.75×now1.25×1.5×2×3×5×10×

At $0.37 today, 0 securities are in the money (0.0% of shares on issue). At double today’s price it is 2.5M (0.8% of shares).

  • Priced supply in the money at the price on the axis — the curve, and the only thing on it. Ten prices, sampled: between two of them the true figure lies between the two.
  • 5.8M (28.5% of the supply above) states no exercise price at all. It cannot be called in or out of the money at any price, which is why it is hatched rather than plotted.
CodeSecurityTypeExercise priceExpiryOn issueSource
RCEAWOptionsPrice-triggered$1.5611 Feb 2027435kFiling
RCEAOOptionsPrice-triggered$0.567 Nov 20292.5MFiling
RCEAPOptionsPrice-triggered$0.8014 Nov 202911.5MFiling
RCEAUOptionsPrice-triggered——1.1MFiling
RCEAQWarrantsPrice-triggered——4.6MFiling

“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column.

1 class ceased in the last 12 months and is not counted above
The company’s own Appendix 2A restates each of these at zero. They are excluded from the overhang, the in-the-money supply and every figure on this page. Each count is the filing’s own count of securities in the class, not a share count — a 2A never states what one security converts into.
  • RCEAHCondition-triggered8.8M securities → 07 Oct 2025 Appendix 2A
Free account
5 option lines on record — In-the-money value & price ladder
What each line is worth in the money today, the price ladder to the next tranche that converts, and the filing description behind every code.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Director dealings

DateDirectorTypeSharesOptionsOtherValueSource
31 July 2026Dr Alan DuntonBuy entitlement/SPP38k———3Y notice
31 July 2026Dr John PrendergastBuy entitlement/SPP38k———3Y notice
31 July 2026Dr Justin WardBuy entitlement/SPP75k1.0M——3Y notice
31 July 2026James GrahamBuy entitlement/SPP25k3.0M——3Y notice
Free account
17 notices on record — Full dealing history
Every change-of-director's-interest notice on record, with direction and consideration.
Free account: 2 full company unlocks every month, no card.
Create free accountSee plans

Ownership

Free account
Top-20 holders & substantial holder notices
Top-20 register snapshot and substantial-holder movements, each linked to its source notice.
Free account: 2 full company unlocks every month, no card.
Create free account

Latest announcements

2 Sept 2026Results of General Meeting
2 Sept 2026General Meeting Presentation
31 Aug 2026Appendix 4G
31 Aug 2026$PAppendix 4E and FY26 Annual Report
19 Aug 2026$PHREC Approves Comparator Study for Pivotal Phase 3 DFI
6 Aug 2026Change of Director's Interest Notices (x4)
4 Aug 2026Cleansing Notice
2 Aug 2026Application for quotation of securities - RCE
31 July 2026Completion of Share Purchase Plan and Shortfall Notice
31 July 2026Application for quotation of securities - RCE
30 July 2026Notice of General Meeting/Proxy Form
30 July 2026U.S. Government Releases US$66.9B AMR Biodefense Strategy
21 July 2026Investor Webinar - Q4 FY26 Investor Presentation Deck
21 July 2026Investor Webinar - 2.30PM (AEST) 21 July 2026
21 July 2026$PQuarterly Activities/Appendix 4C Cash Flow Report
19 July 2026Update - Proposed issue of securities - RCE
19 July 2026Extension to Share Purchase Plan Closing Date
13 July 2026$PVietnamese Patent Granted for RECCE Anti-Infectives
5 July 2026Share Purchase Plan - Letter and Offer Booklet
3 July 2026Cleansing Notice

Headlines link to the source PDFs on the ASX announcements platform. Data as of 12 Sept 2026.